Teva Reports Fourth Quarter and Full Year 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Teva Pharma (TEVA) Reports In-Line Q4 EPS, Offers Guidance
February 8, 2023 7:09 AM ESTTeva Pharma (NYSE: TEVA) reported Q4 EPS of $0.71, in-line with the analyst estimate of $0.71. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $3.88 billion.
GUIDANCE:
Teva Pharma sees FY2023 EPS of $2.25-$2.55, versus the consensus of... More
